CERo Therapeutics
CERO
CERO was delisted on the 30th of October, 2025.
45 hedge funds and large institutions have $137M invested in CERo Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
225% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 4
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
32% more capital invested
Capital invested by funds: $104M → $137M (+$33M)
25% more funds holding
Funds holding: 36 → 45 (+9)
0.01% more ownership
Funds ownership: 0.03% → 0.04% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$5.97M |
| 2 |
HIM
HGC Investment Management
Toronto,
Ontario, Canada
|
+$4.97M |
| 3 |
LA
Linden Advisors
New York
|
+$4.97M |
| 4 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
+$4.97M |
| 5 |
CCM
Context Capital Management
Lajolla,
California
|
+$3.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.04M |
| 2 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
-$1.98M |
| 3 |
CL
CSS LLC
Chicago,
Illinois
|
-$418K |
| 4 |
TI
Telemetry Investments
New York
|
-$304K |
| 5 |
PCM
Pinz Capital Management
New York
|
-$72K |
CERO Hedge Fund Activity: Q1 2022 in Review
45 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q1 2022, worth a combined $137M — up 32% from $104M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new CERO positions and 4 closed out — a net gain of 9 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Periscope Capital, opening a new position worth an estimated $5.97M. The largest seller was UBS O'Connor, exiting entirely with an estimated $2.04M sold.
- 45 institutional investors held CERo Therapeutics (CERO) as of Q1 2022, up from 36 in Q4 2021.
- Funds reported $137M of CERo Therapeutics stock for Q1 2022, up 32% quarter-over-quarter.
- 13 funds opened new CERo Therapeutics positions in Q1 2022 and 4 closed out, a net change of +9 holders.
- The largest CERo Therapeutics buyer in Q1 2022 was Periscope Capital, an estimated $5.97M added.
- The largest CERo Therapeutics seller in Q1 2022 was UBS O'Connor, an estimated $2.04M sold.
Based on aggregated 13F filings for Q1 2022.